These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17937065)

  • 1. Osteoporosis and multiple fractures in an antiretroviral-naive, HIV-positive child.
    Soler Palacin P; Torrent A; Rossich R; Moraga FA; Yeste D; Carreño JC; Encabo G; Figueras C
    J Pediatr Endocrinol Metab; 2007 Aug; 20(8):933-8. PubMed ID: 17937065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring and assessment of bone mineral density in HIV-infected individuals.
    Lawrence D; Cresswell F; Jones E; Jarrett P; Mowete C; Gilleece Y
    Sex Transm Infect; 2016 Dec; 92(8):592. PubMed ID: 27864438
    [No Abstract]   [Full Text] [Related]  

  • 3. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
    Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
    Guo FP; Yu XB; Luo L; Han Y; Qiu ZF; Zuo LY; Li YL; Yu W; Li TS
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV infection and bone disease.
    Compston J
    J Intern Med; 2016 Oct; 280(4):350-8. PubMed ID: 27272530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential predictive factors of osteoporosis in HIV-positive subjects.
    Fausto A; Bongiovanni M; Cicconi P; Menicagli L; Ligabò EV; Melzi S; Bini T; Sardanelli F; Cornalba G; Monforte Ad
    Bone; 2006 Jun; 38(6):893-7. PubMed ID: 16377270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging bone problems in patients infected with human immunodeficiency virus.
    Mondy K; Tebas P
    Clin Infect Dis; 2003 Apr; 36(Suppl 2):S101-5. PubMed ID: 12652379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV infection--a risk factor for osteoporosis.
    Thomas J; Doherty SM
    J Acquir Immune Defic Syndr; 2003 Jul; 33(3):281-91. PubMed ID: 12843738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis.
    Pinzone MR; Moreno S; Cacopardo B; Nunnari G
    AIDS Rev; 2014; 16(4):213-22. PubMed ID: 25300622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV infection, bone metabolism, and fractures.
    Güerri-Fernández R; Villar-García J; Díez-Pérez A; Prieto-Alhambra D
    Arq Bras Endocrinol Metabol; 2014 Jul; 58(5):478-83. PubMed ID: 25166038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.
    Guaraldi G; Orlando G; Madeddu G; Vescini F; Ventura P; Campostrini S; Mura MS; Parise N; Caudarella R; Esposito R
    HIV Clin Trials; 2004; 5(5):269-77. PubMed ID: 15562367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone disorders associated with the human immunodeficiency virus: pathogenesis and management.
    Qaqish RB; Sims KA
    Pharmacotherapy; 2004 Oct; 24(10):1331-46. PubMed ID: 15628831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of bone mineral density in HIV-infected patients.
    Negredo E; Bonjoch A; Clotet B
    Expert Opin Pharmacother; 2016; 17(6):845-52. PubMed ID: 26809940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone disorders in human immunodeficiency virus infection.
    Glesby MJ
    Clin Infect Dis; 2003; 37 Suppl 2():S91-5. PubMed ID: 12942380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone disease in the setting of HIV infection: update and review of the literature.
    Castronuovo D; Cacopardo B; Pinzone MR; Di Rosa M; Martellotta F; Schioppa O; Moreno S; Nunnari G
    Eur Rev Med Pharmacol Sci; 2013 Sep; 17(18):2413-9. PubMed ID: 24089217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. People living with HIV and fracture risk.
    Premaor MO; Compston JE
    Osteoporos Int; 2020 Sep; 31(9):1633-1644. PubMed ID: 32206852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies.
    Walker Harris V; Brown TT
    J Infect Dis; 2012 Jun; 205 Suppl 3(Suppl 3):S391-8. PubMed ID: 22577213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.